There is currently no effective treatment for Friedreich's ataxia (FA), the most common of the hereditary ataxias. The disease is caused by mutations in FRDA that drastically reduce expression levels of the mitochondrial protein frataxin. In FA animal models, a key difficulty is obtaining the precise levels of frataxin expression in the appropriate tissues to provoke pathology without early lethality. To develop strategies to circumvent these problems, conditional frataxin transgenic mice have been generated. We now show that frataxin expression can be eliminated in neurons from these loxP[frda] mice by infection with CRE-expressing herpes simplex virus type 1 (HSV-1) amplicon vectors. We have also achieved in vivo delivery by stereotaxic injection of these CRE-expressing vectors into the brainstem of loxP[frda] mice to generate a localized gene knockout model. These mice develop a behavioral deficit in the rotarod assay detectable after 4 weeks, and when re-injected with HSV-1 amplicon vectors expressing human frataxin complementary DNA (cDNA) exhibit behavioral recovery as early as 4 weeks after the second injection. To the best of our knowledge, this is the first proof of principle of recovery of neurological function by a therapeutic agent aimed at correcting frataxin deficiency.
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There is currently no effective treatment for Friedreich's ataxia (FA), the most common of the hereditary ataxias. The disease is caused by mutations in FRDA that drastically reduce expression levels of the mitochondrial protein frataxin. In FA animal models, a key difficulty is obtaining the precise levels of frataxin expression in the appropriate tissues to provoke pathology without early lethality. To develop strategies to circumvent these problems, conditional frataxin transgenic mice have been generated. We now show that frataxin expression can be eliminated in neurons from these loxP[frda] mice by infection with CRE-expressing herpes simplex virus type 1 (HSV-1) amplicon vectors. We have also achieved in vivo delivery by stereotaxic injection of these CRE-expressing vectors into the brainstem of loxP[frda] mice to generate a localized gene knockout model. These mice develop a behavioral deficit in the rotarod assay detectable after 4 weeks, and when re-injected with HSV-1 amplicon vectors expressing human frataxin complementary DNA (cDNA) exhibit behavioral recovery as early as 4 weeks after the second injection. To the best of our knowledge, this is the first proof of principle of recovery of neurological function by a therapeutic agent aimed at correcting frataxin deficiency.
INTRODUCTION
Similar to many other neurodegenerative diseases, Friedreich's ataxia (FA), the most common of the hereditary ataxias, remains incurable and treatment options are limited. Thus there is a pressing need to explore novel therapeutic strategies such as gene therapy. The discovery that mutations in FRDA, the frataxin gene, cause FA 1 has played a key role in advancing knowledge of the molecular mechanism of the disease and opens the way for developing genebased treatments. Human frataxin is a 210-amino acid protein, although an alternative splice variant has been identified encoding a 196-amino acid form, which differs from the main isoform from amino acid 160 onward. 2 In FA, the most common pathological mutation consists of a GAA triplet expansion within intron 1 of FRDA 1 that reduces messenger RNA expression to extremely low or undetectable levels in homozygotes. A few patients are heterozygotes for GAA expansions but also have point mutations in the other FRDA allele. [3] [4] [5] [6] It is now generally accepted that FA is due to loss of frataxin function, 7 and as the introduction of frataxin transgenes in normal mice has no adverse effects, [8] [9] [10] this disorder is a good model for gene rescue therapy.
The typical neuropathology of FA 11 affects the dorsal root ganglia, spinal cord, medulla oblongata, and the dentate nucleus of the cerebellum, with significant atrophy of the superior cerebellar peduncles. Advanced cases are also characterized by atrophy of Purkinje cells in the cerebellar cortex. For gene delivery into the nervous system, a number of viral vectors, such as those derived from herpes simplex virus type 1 (HSV-1), lentivirus, and adenoassociated virus, show great potential. 12 A previous study of FA gene therapy reported the construction of lentivirus and adenoassociated virus vectors encoding human frataxin complementary DNA (cDNA) and their ability partially to correct the sensitivity of FA patient fibroblasts to oxidative stress, 13 but the use of these vectors in neuronal tissue was not addressed. Although gene transfer experiments with lentiviral and adeno-associated viral vectors are yielding encouraging results in other neuronal systems, HSV-1 vectors possess several advantageous features: they are non-integrating vectors, they are able to accommodate large amounts of DNA (up to 150 kilobases), and because HSV-1 is neurotropic, they have high infectivity in a wide range of neuronal types. We have previously used HSV-1 amplicon vectors for genetic manipulations in the nervous system 14, 15 and, in particular, for gene transfer into the rat inferior olive, 16 a nucleus in the medulla with a key role in motor coordination. 17 To address the neurological aspects of FA more rapidly, in this study we have used HSV-1 amplicon vectors to deliver CRE recombinase into the same brain area of conditional (floxed) FRDA transgenic mice (hereafter referred to as loxP[frda] mice), 18 thus provoking by frda gene excision an anatomically localized neuronal lesion with the known phenotypic effect of motor coordination deficit, 17 which can be quantified easily by tests such as the rotarod assay. 19 Using this model we have gone on to perform gene rescue with an HSV-1 amplicon vector encoding human frataxin cDNA and show that neuronal function
RESULTS

Generation of loxP[frda] mice and HSV amplicon viral vectors expressing CRE and frataxin
To create the tools for manipulating frataxin levels in vivo we first bred mice homozygous for a conditional frataxin allele 18 (Frda L3/L3 ), hereafter referred to as loxP[frda] mice, as described in the Materials and Methods; second, we generated the HSV-1 amplicon vectors (Figure 1 ) pHLC and pHF, which respectively encode cDNAs expressing CRE recombinase and human frataxin tagged with the FLAG epitope 20 ( Figure 1a) . As a control vector we used pHSVlac, 21 an amplicon vector that expresses Escherichia coli β-galactosidase, which is also expressed by pHLC. The lacZ and frataxin transgenes were expressed from the HSV-1 IE4/5 promoter, and CRE recombinase was expressed from the cytomegalovirus immediate early promoter. Transgene expression was confirmed by transient transfection of the plasmid constructs in Vero cells (Figure 1b) and infection by the packaged HSV-1 amplicon vectors in vivo in loxP[frda] mice (Figure 1d and e). We have previously developed an in vivo strategy to deliver HSV-1 amplicon vectors to brainstem by stereotaxic injection into the adult rat inferior olive. 16 To extend this model system to studies in transgenic mice, we first characterized the spread of injected solution in the mouse brain using the neuronal tracer Fluoro-ruby (Figures 1c) . We next examined the expression of pHLC vector injected in vivo in the medulla of loxP[frda] mice. At low vector dosage (3 μl of a stock with a titer of 5 × 10 6 infectious vector units/ml) transgene expression was hardly detectable in tissue sections but β-galactosidase expression was clearly detected (Figure 1d ) using higher vector doses (3 μl of a stock with a titer of 6.7 × 10 7 infectious vector units/ml) and the vector tissue distribution was similar to that marked by Fluoro-ruby. Similarly, transgene expression from the pHF vector was difficult to detect using unconcentrated stocks (3 μl of a stock with a titer of 4.8 × 10 6 infectious vector units/ml) but clearly discernible by FLAG immunohistochemistry of brainstem sections (Figure 1e ) injected using higher doses (3 μl of a stock with a titer of 8.7 × 10 7 infectious vector units/ml).
Alteration of frataxin levels in murine neurons by HSV-1 amplicon vectors
To characterize transgene expression at the biochemical level we infected mouse primary cortical neurons with the packaged HSV-1 amplicon vectors pHLC and pHF (Figure 2a and b) . Using tubulin and actin as controls for loading quantity (Figure 2a , second and third panels), western blots of cell extracts from neuronal cultures from loxP[frda] mice infected with increasing amounts of pHLC vector revealed increasing amounts of β-galactosidase and CRE recombinase expression (Figure 2a , first and fourth panels). The correlated decreasing amounts of frataxin in the same extracts (Figure 2a, bottom panel) indicate that the expressed CRE recombinase was clearly functional and able to inactivate the frda gene in the infected neurons by excising the floxed exon 4 (see ref. 18 and Figure 2c ). We next confirmed our ability to increase frataxin expression using the pHF vector (Figure 2b) . Using species-specific primers we detected human frataxin messenger RNA expression in neurons infected with the pHF vector but not in uninfected controls (Figure 2b , top panel) or neurons infected with pHSVlac (data not shown). Vector infection of neuronal cultures did not affect endogenous mouse frataxin expression (Figure 2b , second panel) with respect to the control glyceraldehyde phosphate dehydrogenase messenger RNA (Figure 2b, third panel) . Using tubulin as a control for loading quantity (Figure 2b, fourth panel) , western blot analysis of extracts from pHF-infected neurons showed that the total amount of frataxin was increased compared with control extracts (Figure 2b, bottom panel) . , β-galactosidase and CRE recombinase (pHLC: lacZ = blue arrow, CRE = green arrow), and human frataxin tagged with the FLAG epitope at the C-terminus (pHF: frda = red arrow, FLAG = purple rectangle). The Escherichia coli lacZ and human frda complementary DNA (cDNA) transgenes were expressed from the HSV1 IE4/5 promoter, and CRE recombinase was expressed from the cytomegalovirus immediate early promoter. In addition to elements for propagation in bacteria (not shown), each amplicon plasmid contained an HSV-1 origin of replication oriS (S), and the HSV-1 packaging signal "a." (b) Transgene expression observed following transfection of the plasmids in Vero cells. Expression of β-galactosidase from the plasmids pHSVlac and pHLC was detected using the substrate X-gal, and expression of the frataxin transgene from pHF was detected by FLAG immunostaining using peroxidase-conjugated secondary antibody. Control untransfected Vero cells were negative for FLAG staining. (c) Injection of Fluoro-ruby (red) into the brainstem in the medulla oblongata. Sections from a mouse sacrificed 1 day after injection were stained by indirect immunofluorescence using an anti-calbindin antibody (green). Scale bar represents 500 μm. The approximate location of the field shown in c is indicated by the boxed area. In mouse models, a well-established method of measuring motor coordination is the rotarod apparatus. To examine the phenotypic effect of frda gene excision we measured rotarod performance before treatment with viral vectors and at 2-week intervals after injection of pHLC and pHSVlac vectors (Figure 3 ) in loxP[frda] mice (n = 3) and wild-type C57/BL6 mice (n = 4). After 4 and 6 weeks, separation between the mean values of the pHLC-and the pHSVlac-injected loxP[frda] mice could be observed (Figure 3, top row) , although the differences between these groups did not quite reach significance (P = 0.057 in both cases). After 8 weeks the rotarod performance difference between the two groups was significant (P = 0.03). This motor coordination deficit was clearly due to frda gene excision, as the difference between the two vectors was not observed when they were injected into wild-type C57/BL6 mice (Figure 3, second row) . Interference of vector injection per se in rotarod performance was not significant, as shown by comparison of untreated mice with those injected with pHLC and pHSVlac (Figure 3 , open circles in second row).
Motor coordination deficit provoked by frda gene excision can be reversed by frda cDNA delivery Because a worsening in rotarod performance could be noted as early as 4 weeks after injection of CRE-expressing vector into loxP[frda] mice, we next investigated whether this motor deficit could be reversed by frda gene delivery with the pHF vector 4 weeks after the frda gene excision (Figure 4) . We compared four groups of mice: those initially injected with pHLC and then with pHF ("rescued" group, n = 6, circles with dotted lines); those initially injected with pHLC and then with pHSVlac ("sham rescued" group, n = 5, circles with solid lines); those only injected initially with pHLC ("lesioned" group, n = 4, squares with solid lines); those only injected initially with pHSVlac ("sham lesioned" group, n = 5, squares with dotted lines). As in the previous experiment (Figure 3) , by 4 weeks, all the mice initially injected with the pHLC vector worsened in previously found to exhibit negligible toxicity in this anatomical area. 16 Indeed, our results show that at these vector concentrations in vivo, changes in motor performance can be more readily detected than transgene expression, which required tenfold higher concentrations. This was due only to the limit of detection sensitivity, as we were able to detect CRE recombinase activity in vivo even at low vector concentrations.
Here we used frda gene excision in olivary neurons to provoke a deficit in rotarod performance that was stable over the 4-month period of the experiment. We also showed recovery from this deficit in motor coordination by restoration of frataxin expression using a HSV-1 amplicon vector. This functional recovery was surprisingly complete, in view of the fact that frataxin restoration can occur only in the overlapping subset of neurons transduced by both the first and second injections. Several explanations are possible. First, frda gene rescue of one subset of neurons may aid in the survival of others, by stimulating the generation of trophic factors and/or connections. Second, similar results were obtained by Fernandez et al., 28 who used an ataxic rat model in which they provoked ablation of more than 80% of the inferior olive with 3-acetylpyridine. In this study, delayed insulin-like growth factor 1 treatment resulted in the survival of only 27% of the total olivary neurons but, remarkably, total functional recovery was observed. These authors attribute functional recovery not only to increased neuronal survival but also to induced axonal sprouting. Third, when recovery of motor coordination reaches a certain threshold, other compensatory mechanisms of learning and/or motor function may be sufficient to achieve a normal level of performance in given tasks such as the rotarod test.
The level of frataxin protein expressed by our pHF vector was similar to the endogenous levels observed in wild-type neurons rotarod performance compared with those injected with pHSVlac. Notably, by 4 weeks after the second injection (week 8) the mean values of the rescued group had reverted to those of the sham-lesioned group and were separated from the mean values of the lesioned group (Figure 4) . The mean values of the sham rescued group were indistinguishable from those of the lesioned group, indicating that the second injection event had no non-specific rescue effect. This pattern of differences between the four groups was maintained throughout the remainder of the experiment (12 weeks after the second injection, week 16), with significant differences being observed between rescued and lesioned mice (P = 0.03) at the last time point measured (Figure 4) . These results indicate that the neurological defect provoked by elimination of the frda gene in the brainstem/ cerebellum can be reversed by re-expressing frda at a later time point. In this study the delay between lesion and rescue was 1 month, the minimum period required to observe a decrease in rotarod performance.
DISCUSSION
In this study our main goal was to generate proof-of-principle data for frataxin gene therapy in the treatment of FA neuropathology. As animal models, we have generated localized frataxin knockout mice by targeting the inferior olive of transgenic loxP[frda] mice with CRE recombinase viral vectors. The chief advantage of our model is that the adult mouse brain contains only ~30,000 olivary neurons 22, 23 and histological analyses of various ataxic mutant mice show olivary neuronal deficits of between 20 and 60%. [23] [24] [25] [26] [27] Thus our model should be sensitive to relatively low vector dosage, in the range of tens of thousands of infectious particles, permitting the use of unconcentrated HSV-1 amplicon stocks, which we have Figure 1d ), indicating that we had obtained physiologically relevant levels of transgene expression. This may be particularly important, because high-level overexpression of frataxin by lentiviral or adenoassociated viral vectors has been previously reported to be toxic in FA patient fibroblasts. 13 We have recently demonstrated rescue of the FA fibroblast phenotype with negligible toxicity by using HSV-1 amplicon vectors bearing the entire FRDA locus, 29 which results in physiological expression levels. It is also known that frataxin expression is reduced to ~40% in asymptomatic human carriers of pathogenic FRDA mutations, 30 indicating that highlevel frataxin expression is not required for therapeutic recovery. In this work, despite the fact that expression from viral promoters has been observed to diminish significantly in neurons in vivo, we have used both the cytomegalovirus and the HSV-1 IE4/5 promoters to drive transgene expression for several reasons: first, we needed only transient expression of CRE recombinase (driven by the cytomegalovirus promoter) to effect frda excision in loxP [frda] neurons; second, in contrast to other brain areas, 31 we have previously observed that in the inferior olive and cerebellum, expression from the IE4/5 promoter is stable for at least 40 days; 16 third, for this proof-of-concept study, the simplest amplicon vectors were used for ease of construction. Our ongoing studies are focused on the use of our HSV-1 amplicon vectors bearing the whole FRDA genomic locus, 29 as the presence of the native regulatory sequences, including promoter, enhancer, and silencer elements, will likely produce physiological and stable expression.
All therapeutic strategies aimed at alleviating neurodegeneration in FA and many other neurological conditions have failed so far, emphasizing the need to explore other options such as gene therapy. Transgene delivery to the nervous system is by no means an easy task; introduction of vectors into the bloodstream is generally an ineffective way to target them into neurons, and most methods rely upon direct injection into nervous tissue, which in turn results in transduction predominantly in the area near the injection site. HSV-1 is a promising tool for nervous system gene therapy 32 for a number of reasons: it naturally targets neurons for infection and can be transported throughout the nervous system to establish lifelong persistence; the virion has an extremely large packaging capacity; and the genome remains episomal in infected cells, thus avoiding a risk of insertional mutagenesis. Here we have described the functional validation of HSV-1 viral vectors by delivery into the brainstem using stereotaxic injection to achieve focal gene deletion and rescue in neurons that affect motor coordination. During the preparation of this manuscript new transgenic knock-in mouse FA models were reported that closely mimic the human disease because they have FRDA transgenes that bear pathological GAA repeat expansions. 33 These whole-animal models will greatly facilitate our ongoing studies, which are aimed at identifying the means to achieve suitable penetration of our therapeutic vectors into FA-relevant neuronal targets.
MATERIALS AND METHODS
Reagents and plasmids. The polyclonal antiserum directed against calbindin (1:500) was from Chemicon (Temecula, CA), as was the frataxin monoclonal antibody 1G2 (1:100). The 1,250 anti-frataxin polyclonal antiserum (1:1,000) was a kind gift from Helene Puccio. Both frataxin antibodies recognize both the mouse and human proteins, but in our hands only the 1G2 antibody was suitable for immunocytochemistry and only the 1,250 antiserum was suitable for western blot analysis. Anti-FLAG polyclonal antiserum (1:5,000) was a kind gift from Rachael L. Neve, and the polyclonal antibody against β-galactosidase (1:5,000) was from MP Biomedicals (Eschwege, Germany). Monoclonal antibodies specific for β-tubulin (1:1,000) and β-actin (1:1,000) were from Sigma (Madrid, Spain), and the polyclonal antibody against CRE recombinase (1:1,000) was from Abcam (Cambridge, UK). FLAG immunochemistry was performed with peroxidase-conjugated secondary antibody (Amersham, Buckinghamshire, UK) using the substrate 3,3′-diaminobenzidine (Sigma, Madrid, Spain). Calbindin and β-galactosidase immunofluorescence was performed using Alexa 488-conjugated secondary antibodies (Invitrogen, Barcelona, Spain). The pHLC plasmid was generated by inserting the CRE recombinase cDNA driven by the cytomegalovirus immediate early promoter as an AseI/XbaI fragment derived from pCI-cre (a kind gift from Fabio Rossi) into pHSVlac. 21 We generated the transgene encoding the frataxin-FLAG fusion protein by PCR amplification from a human frda cDNA clone Mice were analyzed in the accelerating rotarod test before treatment (week 0) and at 2-week intervals after stereotaxic injection in the brainstem of 3 μl containing either pHSVlac vector (4.5 × 10 6 infectious vector units/ml) or pHLC vector (4.7 × 10 6 infectious vector units/ml). Immediately after the rotarod test in week 4, mice were re-injected in the brainstem with 3 μl containing either pHSVlac vector (4.5 × 10 6 infectious vector units/ml) or pHF vector (4.8 × 10 6 infectious vector units/ml). Mean values are shown with standard errors of the means (vertical bars). Double-headed arrows linking symbols on the right of the graphs for weeks 6, 10, and 16 indicate levels of significance between the indicated groups: dotted line, 0.05 < P < 0.1; solid line P < 0.05. in pCR-Script-SK+ (a kind gift from Francesc Palau and Jose Gonzalez Castaño) using the T7 primer at the 5′ end and the oligonucleotide 5′-GTCACTAGTGAATTCACGATTTATCGTCATCGTCTTTGTAG TCCATAGCATCTTTTCCGGAATAGG-3′ at the 3′ end. The PCR product was then cloned as a BamHI/EcoRI fragment into pHSVpuc 34 to generate pHF. Reverse-transcriptase PCR analysis of human FRDA expression in mouse primary cortical neurons was performed as previously described.
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Viral vectors. HSV-1 amplicon vectors were packaged using as helper virus the ICP27 deletion mutant 5dl1.2 virus 35 grown on the complementing 2-2 cell line. 36 Vector packaging was performed as previously described.
14 For high-dose experiments, HSV-1 amplicons were concentrated by centrifuging viral preparations through a 25% sucrose cushion at 100,000g for 3 hours and re-suspending the pellet in phosphate-buffered saline (PBS) overnight at 4 °C. Titering of infectious vector units (ivu) was performed by Xgal staining (pHSVlac and pHLC) or FLAG immunostaining (pHF) in Vero cells, and titering of helper virus plaque-forming units (pfu) in 2-2 cells was performed as previously described.
14 Titers of unconcentrated HSV-1 amplicon stocks were 4.5 × 10 6 ivu/ml and 1.5 × 10 6 pfu/ml for pHSVlac, 4.7 × 10 6 ivu/ml and 5 × 10 6 pfu/ml for pHLC, and 4.8 × 10 6 ivu/ml and 6 × 10 6 pfu/ml for pHF. Titers of the concen trated amplicon stocks were 6.7 × 10 7 ivu/ml and 8.0 × 10 7 pfu/ml for pHLC and 8.7 × 10 7 ivu/ml and 7.0 × 10 7 pfu/ml for pHF. No wildtype HSV-1 revertants were found in any of the stocks within the sens itivity of our pfu assay in Vero cells (10 −6 ). HSV-1 amplicon vectors were packaged and used to infect cells in culture as well as adult mice (intracerebral stereotaxic injection) in P2 facilities. Laboratory facilities at the Centro de Biología Molecular are subject to regular inspection by government authorities and comply with the following national regulations: Royal Decree 664/1997 (Protection of workers against risks related with exposure to biological agents during work); Royal Decree 951/1997 (requirement for legal approval of the confined use, deliberate release and commercialisation of genetically modified organisms, with the aim of preventing risks to human health and the environment).
Neuronal cultures. Cortical primary neurons were cultured according to an established protocol. 37, 38 In brief, 17-day-old embryos were removed from a pregnant female mouse and dissected in pre-chilled Hank's buffered salt solution. After removal of the meninges, striatum, and hippocampus, the intact cortices were cut into small pieces and then incubated in a 0.25% trypsin (Sigma, Madrid, Spain), 1 mg/ml DNaseI (Roche, Barcelona, Spain) solution in Hank's buffered salt solution without calcium and magnesium for 15 minutes at 37 °C, with gentle shaking every 3-4 minutes. The dissociated cells were then re-suspended and plated in minimum essential medium supplemented with 0.6% glucose and 10% horse serum (Invitrogen, Barcelona, Spain). The medium was changed after 4 hours to Neurobasal culture medium supplemented with B-27, 2 mmol GlutaMaxI (both from Invitrogen, Barcelona, Spain), and a mix of penicillin and streptomycin (100 U/ml and 100 μg/ml, respectively). The cells were plated at a density of 1 × 10 5 cells/cm 2 onto poly-l-lysineprecoated surfaces, and one third of the medium was replaced every 3 days. To avoid glial proliferation, 5 μmol Ara-C was added 24 hours after plating.
Western blot analysis. For protein extracts, cells were washed once with PBS, placed on ice, and then homogenized in a buffer containing 20 mmol HEPES, pH 7.4; 100 mmol sodium chloride (NaCl); 100 mmol sodium fluoride; 1% Triton X-100; 1 mmol sodium orthovanadate; 5 mmol EDTA; and the COMPLETE protease inhibitor cocktail (Roche, Barcelona, Spain). After determination of the protein content using the Bradford assay, samples containing the same amount of protein were mixed with electrophoresis buffer containing sodium dodecylsulfate, boiled for 5 minutes, and separated by gel electrophoresis in the presence of sodium dodecylsulfate on 6-10% acrylamide gels. The proteins were then transferred to nitrocellulose membranes following standard procedures and the membranes were blocked with 10% non-fat dried milk in PBS, 0.2% Tween-20. The blocked membranes were incubated overnight with primary antibodies diluted in blocking solution at 4 °C. The filters were then washed three times in PBS, 0.2% Tween-20 and incubated with the corresponding peroxidase-conjugated secondary antibody for 1 hour at room temperature. After three further washes with PBS the immunoreactive proteins were visualized using an enhanced chemiluminescence detection system (Amersham,Buckinghamshire, UK).
Mouse maintenance. Transgenic mice hemizygous for the conditional frataxin allele (Frda +/L3 ) 18 were kindly provided by Helene Puccio, Michel Koenig, and Ignacio Torres. These were bred in a C57/BL6 genetic background to generate homozygous Frda L3/L3 mice (referred to in the text as loxP[frda] mice) using the following PCR primers for genotyping: P2neo, P3, 18 and MOF1: 5′-AACGTTACTCTTAGGGTCAG-3′. The primer pair P3 + P2neo generates an ~250-base pair PCR product specific for the presence of the L3 allele, and the primer pair P3 + MOF1 generates an ~350-base pair PCR product specific for the wild-type allele. Rotarod test for motor coordination. Motor coordination was determined in a rotarod apparatus (Ugo Basile, Italy). Animals were tested using the accelerating rotating rod protocol, from 4 to 40 rpm over 5 minutes followed by 5 minutes at maximum velocity. Latency was defined as the duration for which the mice were able to maintain their equilibrium on the accelerating rod until falling off, and was recorded in four consecutive trials. In the experiments shown in Figure 3 , the four trials were conducted in the mornings and afternoons over 2 days with a minimum of 4 hours between trials. In the experiments shown in Figure 4 , trials were conducted on consecutive days. Mice that were still on the rod at the end of the trial were scored with a latency of 10 minutes. One week before the first measurement, the mice received a training session to familiarize them with the procedure. Results were analyzed using a repeated measure analysis of variance test with three factors: trial number (fixed); vector (fixed); animals (variable), nested in vector and crossed with trial number.
Stereotaxic injection. Mice 3-6 months of age were anesthetized using isofluorane and when they no longer demonstrated the footpad pinch reflex, they were positioned in a Stoelting Lab StandardJ stereotaxic instrument fitted with a mouse gas mask (#51609; Stoelting, Wood Dale, IL) and a burr hole was drilled into the skull at the midline, 2.7 mm rostral from lambda. A 26-gauge needle with 30° bevel attached to a 5-μl Hamilton syringe was aligned over the burr hole and then lowered into the brain 5.5 mm deep from the surface of the skull. Injections of 3 μl HSV-1 amplicon vector or Fluoro-ruby (Molecular Probes, Eugene, OR) were performed over 5 minutes, after which the needle was withdrawn slowly over 3 minutes.
After surgery, the incision was closed with sutures and the animals were allowed to recover on a heated pad before being returned to their cages. For histochemical analyses brain tissues were fixed by perfusion with cold paraformaldehyde (4% in PBS), cryoprotected by overnight incubation in 30% sucrose, and sectioned at −20 °C in 30-μm slices after embedding in Tissue Tek (Sakura Finetek Europa, Zoeterwoude, The Netherlands).
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